YOLFTbeta
Uniqure NV

Uniqure NV

QURE · NASDAQ · Healthcare / Biotechnology

23.81USD-0.82 (-3.33%)

Price History

Full chart

Market Stats

Previous Close24.63
Open24.50
Day Range23.34 – 24.50
52-Week Range8.73 – 71.50
Volume1.39M
Market Cap2.71B
P/E (TTM)0.00
Forward P/E27.93
EPS-4.16
Dividend Yield0.00%
Beta0.94
50-Day Avg44.47
200-Day Avg29.65

About

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Matthew Craig Kapusta CPA
  • Employees221
  • HeadquartersPaasheuvelweg 25, Amsterdam, Netherlands, 1105 BP, USA
  • Websitehttps://www.uniqure.com

Leadership

  • Mr. Matthew Craig Kapusta CPACEO & Executive Director · b. 1972
  • Mr. Christian KlemtCFO, Principal Financial Officer & GM of Amsterdam Site · b. 1973
  • Dr. Jeannette Potts J.D., Ph.D.Chief Legal & Compliance Officer and Corporate Secretary · b. 1962
  • Dr. Walid Abi-Saab M.D.Chief Medical Officer · b. 1965
  • Prof. Hugo KatusChairman of Scientific Advisory Board and Managing Director of UniQure-Germany
  • Dr. Amin Abujoub Ph.D.Chief Technical Operations Officer
  • Mr. Richard Porter Ph.D.Chief Business & Scientific Officer · b. 1968
  • Ms. Chiara Elizabeth RussoSenior Director of Investor Relations
  • Dr. Tamara Tugal Ph.D., MBABusiness Development Director
  • Ms. Erin BoyerChief People & Culture Officer

Financials

Income Statement

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--4.06M5.70M10.30M25.10M13.11M11.28M7.28M37.51M524.00M106.48M15.84M27.12M16.10M
Growth (%)---+40.19%+80.87%+143.57%-47.78%-13.91%-35.48%+415.23%+1296.82%-79.68%-85.12%+71.17%-40.64%
Cost of Revenue-13.49M1.10M43.58M638.49K72.69M67.41M73.06M94.74M122.40M24.98M3.34M13.63M18.33M1.69M
Gross Profit--13.49M2.96M-37.88M9.67M25.10M-54.30M-61.78M7.28M-84.89M499.03M103.14M2.21M8.79M14.41M
Gross Margin--72.82%-664.91%93.80%100.00%-414.30%-547.47%100.00%-226.28%95.23%96.86%13.98%32.42%89.53%
Operating Expense-5.28M34.08M3.26M84.49M97.04M17.66M26.46M128.42M40.54M188.41M246.30M285.09M193.09M202.24M
Operating Income-22.22M-18.77M-31.12M-41.14M-74.82M-71.95M-71.96M-88.23M-121.14M-125.43M310.62M-143.16M-282.87M-184.29M-187.83M
Operating Margin---765.72%-722.18%-726.12%-286.66%-549.00%-781.92%-1663.78%-334.34%59.28%-134.44%-1785.46%-679.58%-1166.77%
EBITDA-22.63M-18.09M-33.71M-45.71M-72.48M-65.86M-69.74M-74.01M-113.72M-126.97M319.00M-108.02M-253.10M-160.75M-116.59M
EBITDA Margin---829.42%-802.40%-703.35%-262.40%-532.06%-655.91%-1561.90%-338.46%60.88%-101.44%-1597.55%-592.74%-724.23%
Net Income-22.42M-19.46M-37.03M-45.04M-78.15M-73.37M-80.39M-83.30M-124.20M-125.02M329.59M-126.79M-308.48M-239.56M-198.97M
Net Income Margin---911.32%-790.61%-758.41%-292.35%-613.33%-738.25%-1705.82%-333.27%62.90%-119.07%-1947.09%-883.35%-1236.00%
R&D20.09M13.53M18.20M41.26M51.15M72.51M72.38M74.81M94.74M122.40M143.55M197.59M214.86M143.78M140.67M
R&D as % of Total Revenue--447.91%724.27%496.35%288.91%552.25%662.97%1301.15%326.28%27.39%185.56%1356.21%530.19%873.85%
Interest Expense509.36K109.77K1.24M2.02M2.57M2.17M2.48M2.16M3.81M3.83M7.47M11.70M41.56M63.74M61.99M
Interest Expense % of Total Revenue--30.45%35.44%24.96%8.65%18.88%19.14%52.33%10.20%1.43%10.99%262.31%235.04%385.10%

Balance Sheet

Currency: USD2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets30.19M7.52M7.36M53.81M116.48M264.69M190.26M208.88M273.91M448.63M340.39M809.18M704.96M831.69M556.54M824.91M
Total Liabilities12.03M10.88M7.95M46.13M64.09M134.06M126.63M118.93M94.30M125.57M96.49M213.40M228.96M624.02M563.29M626.01M
Total Equity18.17M-3.36M-592.48K7.68M52.39M130.63M63.63M89.94M179.61M323.06M243.91M595.78M476.01M207.67M-6.75M198.90M
Cash23.75M1.43M347.82K32.88M64.71M222.52M132.50M159.37M234.90M377.79M244.93M556.26M228.01M241.36M158.93M80.24M
Total Debt293.92K233.30K595.13K11.17M20.96M21.18M20.24M21.59M43.47M73.06M71.54M135.72M142.89M138.41M66.06M536.59M
Net Debt-23.46M-1.19M247.31K-21.71M-43.76M-201.34M-112.26M-139.20M-199.43M-304.73M-173.39M-420.53M-85.12M-102.95M-92.87M456.35M

Cash Flow

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-21.65M-14.91M-5.71M-30.92M18.78M-72.19M-64.27M-76.04M-98.68M-134.83M287.96M-145.06M-145.93M-182.73M-177.96M
Investing Cash Flow-209.97K-1.10M-8.25M-24.87M-9.31M-17.79M-6.15M-4.25M-6.65M-9.48M-67.39M-182.73M-205.69M162.97M-321.62M
Financing Cash Flow139.98K14.91M46.46M84.46M150.40M2.44M90.07M157.96M248.82M7.44M94.86M1.45M362.72M-59.49M415.40M
Capital Expenditure400.49K1.25M8.27M23.27M9.41M17.17M5.58M4.25M6.65M9.48M17.44M17.69M7.15M3.37M439.00K
Free Cash Flow-22.05M-16.16M-13.98M-54.19M9.36M-89.36M-69.85M-80.28M-105.33M-144.31M270.52M-162.75M-153.08M-186.10M-177.96M
Dividends Paid-----00--------
FCF to OCF101.85%108.38%244.78%175.26%49.86%123.79%108.69%105.58%106.74%107.03%93.94%112.19%104.90%101.84%100.00%
Dividend Paid to FCF-----0.00%0.00%--------

Earnings

Report DateMar 26, 2014Jun 6, 2014Sep 2, 2014Dec 1, 2014Jun 11, 2015Aug 27, 2015Nov 30, 2015Apr 4, 2016Aug 25, 2016Nov 22, 2016Mar 15, 2017May 9, 2017Aug 8, 2017Nov 1, 2017Mar 14, 2018Apr 30, 2018Aug 8, 2018Nov 6, 2018Feb 28, 2019Apr 29, 2019Jul 29, 2019Oct 28, 2019Mar 2, 2020Apr 29, 2020Jul 30, 2020Oct 27, 2020Mar 1, 2021May 10, 2021Jul 26, 2021Oct 25, 2021Feb 25, 2022May 2, 2022Aug 8, 2022Nov 2, 2022Feb 27, 2023May 9, 2023Aug 1, 2023Nov 7, 2023Feb 28, 2024May 7, 2024Aug 1, 2024Nov 5, 2024Feb 24, 2025May 9, 2025Jul 29, 2025Nov 10, 2025Mar 2, 2026May 5, 2026Jul 29, 2026Nov 9, 2026
EPS Estimate--0.30-0.46-0.53-0.400.36-0.72-0.61-0.78-0.77-0.56-0.58-0.71-0.54-0.77-0.61-0.52-0.54-0.66-0.63-0.67-0.74-0.73-0.73-0.52-0.761.52-0.772.18-0.91-0.81-0.79-0.91-1.11-0.89-0.872.81-0.72-1.46-1.16-1.16-0.93-0.52-0.93-0.76-0.75-0.92-0.75-0.81-0.84
EPS Actual-0.49-0.52-0.51-0.51-0.69-0.87-0.67-0.48-0.77-0.54-0.51-0.74-0.71-0.34-0.91-0.49-0.49-0.52-0.59-0.66-0.75-0.52-0.96-0.58-0.82-1.02-0.01-0.757.23-0.680.17-0.95-0.83-1.030.15-1.48-1.31-1.75-1.53-1.26-1.08-0.84-1.44-0.73-0.60-1.19-0.47-0.73-1.22-
Surprise--73.33%-10.87%3.77%-72.50%-341.67%6.94%21.31%1.28%29.87%8.93%-27.59%0.00%37.04%-18.18%19.67%5.77%3.70%10.61%-4.76%-11.94%29.73%-31.51%20.55%-57.69%-34.21%-100.66%2.60%231.65%25.27%120.99%-20.25%8.79%7.21%116.85%-70.11%-146.62%-143.06%-4.79%-8.62%6.90%9.68%-178.82%21.51%21.05%-58.67%48.31%2.67%-50.62%-
Timing-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap2.71B
Enterprise Value2.22B
Trailing P/E0.00
Forward P/E27.93
PEG Ratio0.00
Price / Sales145.29
Price / Book9.15
EPS-4.16
Book Value4.67
Revenue (TTM)18.67M
Gross Profit (TTM)-114.71M
EBITDA-182.92M
Profit Margin0.00%
Operating Margin-872.23%
Return on Equity-157.61%
Return on Assets-15.72%
Shares Outstanding69.37M
Shares Float57.52M
Beta0.94
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 13 analystsTarget 68.20
  • Strong Buy
    9
  • Buy
    2
  • Hold
    2

Ownership Breakdown

Institutions
97.96%
Insiders
1.26%
Retail / Other
0.78%

Top Institutional Holders

  • venBio Select Advisor LLC
    5.96M8.59%
  • Aberdeen Group PLC
    2.85M4.11%
  • JPMorgan Chase & Co
    2.84M4.09%
  • RTW INVESTMENTS, LLC
    2.59M3.73%
  • State Street Corp
    2.26M3.26%
  • Orbimed Advisors LLC
    2.14M3.08%
  • FMR Inc
    1.74M2.51%
  • BlackRock Inc
    1.73M2.50%
  • Jennison Associates LLC
    1.56M2.25%
  • Two Sigma Investments LLC
    1.46M2.11%
  • Two Seas Capital LP
    1.30M1.87%
  • The Goldman Sachs Group Inc
    1.26M1.82%
  • MPM Oncology Impact Management LP
    1.23M1.77%
  • Susquehanna International Group, LLP
    1.00M1.45%
  • Siren, L.L.C.
    1.00M1.44%
  • Balyasny Asset Management LLC
    964.29K1.39%
  • Citadel Advisors Llc
    910.34K1.31%

Top Fund Holders

  • State Street® SPDR® S&P® Biotech ETF
    2.52M3.64%
  • JPMorgan Growth Advantage A
    1.77M2.55%
  • JPMorgan Mid Cap Growth I
    1.25M1.80%

Stock Splits

  • Jan 31, 20141:5